194 related articles for article (PubMed ID: 38490995)
1. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
Chenchula S; Atal S; Uppugunduri CRS
Pharmacogenomics J; 2024 Mar; 24(2):9. PubMed ID: 38490995
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
Chan SL; Ng HY; Sung C; Chan A; Winther MD; Brunham LR; Wee HL
Pharmacogenomics J; 2019 Aug; 19(4):401-410. PubMed ID: 30250149
[TBL] [Abstract][Full Text] [Related]
3. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
[No Abstract] [Full Text] [Related]
4. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients.
Kim K; Magness JW; Nelson R; Baron V; Brixner DI
J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
7. Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil.
Camargo AC; Matte U; Botton MR
Expert Opin Drug Saf; 2023; 22(7):621-627. PubMed ID: 36794346
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
9. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Duarte JD; Dalton R; Elchynski AL; Smith DM; Cicali EJ; Lee JC; Duong BQ; Petry NJ; Aquilante CL; Beitelshees AL; Empey PE; Johnson JA; Obeng AO; Pasternak AL; Pratt VM; Ramsey LB; Tuteja S; Van Driest SL; Wiisanen K; Hicks JK; Cavallari LH;
Genet Med; 2021 Dec; 23(12):2335-2341. PubMed ID: 34282303
[TBL] [Abstract][Full Text] [Related]
10. Clinical implementation of preemptive pharmacogenomics in psychiatry.
Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.
van der Wouden CH; Bank PCD; Özokcu K; Swen JJ; Guchelaar HJ
Genes (Basel); 2019 May; 10(6):. PubMed ID: 31146504
[TBL] [Abstract][Full Text] [Related]
12. The role of pharmacogenomics in adverse drug reactions.
Cacabelos R; Cacabelos N; Carril JC
Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
[TBL] [Abstract][Full Text] [Related]
13. Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing.
Chan SL; Liew HZW; Nguyen F; Thumboo J; Chow WC; Sung C
Br J Clin Pharmacol; 2021 Mar; 87(3):886-894. PubMed ID: 32559336
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.
Samwald M; Xu H; Blagec K; Empey PE; Malone DC; Ahmed SM; Ryan P; Hofer S; Boyce RD
PLoS One; 2016; 11(10):e0164972. PubMed ID: 27764192
[TBL] [Abstract][Full Text] [Related]
15. Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.
Kim GJ; Lee SY; Park JH; Ryu BY; Kim JH
Drug Saf; 2017 Jan; 40(1):65-80. PubMed ID: 27638658
[TBL] [Abstract][Full Text] [Related]
16. Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.
Claudio-Campos K; Padrón A; Jerkins G; Nainaparampil J; Nelson R; Martin A; Wiisanen K; Smith DM; Strekalova Y; Marsiske M; Cicali EJ; Cavallari LH; Mathews CA
Clin Transl Sci; 2021 Mar; 14(2):589-598. PubMed ID: 33166056
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics: Prescribing Precisely.
Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
[TBL] [Abstract][Full Text] [Related]
18. The Translational Approaches to Personalized Health Collaborative: Pharmacogenomics for African American Older Adults.
J Sargent L; Mackiewicz M; Roman Y; Diallo A; Russell S; Falls K; Zimmerman KM; Dixon DL; Prom-Wormley E; Hobgood S; Lageman SK; Zanjani F; Price ET
Clin Transl Sci; 2021 Mar; 14(2):437-444. PubMed ID: 33026148
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
[TBL] [Abstract][Full Text] [Related]
20. Clinical association between pharmacogenomics and adverse drug reactions.
Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
